Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)

Publication | Closed Access

DOI

Citations

References

2014

Year

Ágnes Ruzsa, Mehmet Şen, Mark D. Evans, L. W. Lee, Katalin Hidéghety, Sylvie Rottey, Petr Klimak, Petra Holečková, Jérôme Fayette, Tibor Csőszi,

Investigational New Drugs

MedicinePathologyEmd 1201081Second-line Cetuximab-naïve PatientsHead And Neck CancerCancer TreatmentPhase 2Neck OncologyOncologyRadiation OncologyCancer ResearchMolecular Oncology